*As of September 2025.1
†Between August 2024 and August 2025.2
‡Source: Specialty Pharmacy Data from August 2024 to August 2025; n=941 which represents approximately 99% of FABHALTA fills. For remaining patients, the out-of-pocket cost for the product varies and may be a high as the total cost of the product.3
Enter your NPI number on your ZIP Code to see local FABHALTA coverage for your patients.
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA
FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life threatening or fatal if not recognized and treated early.
Because of the risk of serious infections caused by encapsulated bacteria, FABHALTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.
FABHALTA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
Definitions
IgAN, immunoglobulin A nephropathy; NPI, National Provider Identifier.
Reference
1. Data on file. FABHALTA MMIT coverage. Novartis Pharmaceuticals Corp; 2025.
2. Data on file. FABHALTA Novartis Hub Patient Service and Specialty Pharmacy payer coverage outcome data. Novartis Pharmaceuticals Corp; 2025.
3. Data on file. FABHALTA Specialty Pharmacy data. Novartis Pharmaceuticals Corp; 2025.